A University of Florida engineering team has created the world’s first CRISPR system guided by DNA rather than RNA, a fundamental shift that could make gene-editing tools safer, cheaper and far more precise — with implications for cancer treatment, infectious disease diagnostics, and beyond.
A team of engineers at the University of Florida has upended one of the most foundational assumptions in gene-editing science: that CRISPR must be guided by RNA. Their new system, published May 15 in Nature Biotechnology, uses DNA as the guide molecule instead — a switch that could make CRISPR-based therapies and diagnostics safer, more affordable, and dramatically more precise.
The research, led by Piyush Jain, an associate professor and Shah Rising Professor in the Department of Chemical Engineering at UF, was first posted as a preprint in 2024 and has now received formal peer-reviewed publication. It marks the first time scientists have engineered a CRISPR enzyme — specifically CRISPR-Cas12 — to seek out RNA targets using a DNA guide rather than the RNA guide that has defined the field for decades.
Why RNA Targeting Matters
To appreciate the significance of the breakthrough, it helps to understand how genetic information flows inside a cell. DNA is the master blueprint — the permanent instruction manual stored in every cell’s nucleus. But cells don’t act directly on that blueprint. Instead, they transcribe working copies called messenger RNA, which carry instructions for building proteins and executing cellular functions.
“Those RNA copies are like Xerox copies of the original manual, and sometimes those copies have errors,” Jain said in a news release.
Those errors matter enormously in disease. In cancer, for instance, cells can churn out faulty RNA copies that instruct unchecked growth. Targeting RNA rather than DNA offers an appealing middle path: scientists can intervene in real time without making permanent changes to the underlying genetic code.
RNA-targeting CRISPR tools have been in development for several years, but they come with notable limitations. Current systems use RNA molecules as guides to locate target RNA inside the cell — and that creates a reliability problem.
“Existing RNA-targeting CRISPR systems rely on RNA guides to find their targets,” Jain added. “While effective, they can sometimes affect unintended molecules, creating off-target effects. They can also be costly and less stable.”
The DNA Difference
Jain’s team engineered around those limitations by replacing the RNA guide with a DNA guide. DNA is inherently more chemically stable than RNA — it doesn’t degrade as quickly, it’s easier to synthesize in bulk, and it’s significantly cheaper to manufacture at scale. By pairing that stability with the CRISPR-Cas12 enzyme’s natural ability to cut and bind nucleic acids, the researchers created a system that can identify and act on specific RNA molecules with greater accuracy than existing approaches.
The team reports that their system reduces unintended off-target effects by orders of magnitude compared with current RNA-guided tools, a claim that, if borne out in further trials, would represent a major leap in therapeutic safety. The system was also tested in clinical diagnostic contexts, demonstrating 100% accuracy in detecting hepatitis C and showing the ability to catch HIV early — without the expense and fragility of RNA-based detection reagents.
“While RNA molecules degrade quickly, DNA can remain intact for long periods,” added Jain.
That durability has real-world consequences. RNA-based reagents require cold-chain storage and careful handling — a significant barrier in low-resource clinical settings. DNA guides could simplify storage and distribution, making CRISPR-based diagnostics more accessible globally.
Fixing the Copies Without Touching the Manual
One of the most compelling aspects of the new approach is what it doesn’t do: it leaves the DNA blueprint untouched. By operating exclusively at the RNA level, the system gives clinicians and researchers a reversible, more cautious first line of intervention.
Jain described the system as giving scientists a way to fix or tune the instructions a cell is using in real time, without immediately changing the DNA. That added layer of control could prove critical for patient safety — allowing physicians to reduce disease-causing activity, such as runaway cell-growth signals, and assess outcomes before committing to permanent genetic edits.
A team effort rooted in unconventional thinking
The study’s co-first authors — all from Jain’s lab — are doctoral student Carlos Orosco, postdoctoral researcher Boyu Huang, and former doctoral student Santosh Rananaware. Orosco reflected on the persistence required to pursue such an unorthodox hypothesis.
“This project required a great deal of persistence and creativity because we were exploring an idea that challenged conventional thinking,” Orosco said in the news release. “It was a powerful reminder that scientific progress often begins by questioning ideas we take for granted.”
That questioning paid off. After decades of research and tens of thousands of studies built on RNA-guided CRISPR systems, the UF team has introduced a fundamentally different paradigm for directing one of biology’s most powerful molecular tools.
What Comes Next
The technology is still in its early stages, but the pipeline looks promising. Federal agencies including the National Institutes of Health, the Food and Drug Administration, and the Advanced Research Projects Agency for Health are actively pushing development of next-generation gene-editing tools toward clinical use.
Jain estimates that highly targeted early applications — particularly those involving cells or tissues treated outside the body, such as in organ transplantation — could emerge within a few years. His lab is already exploring how related DNA-guided tools might be used to repair donor organs before transplant surgery.
Broader clinical use, as with any gene-editing platform, will require extensive additional testing and regulatory approval.
“At its core, this is about giving us better control,” Jain added. “Not just rewriting the instruction manual but also precisely managing how those instructions are used.”
For students studying bioengineering, molecular biology or medicine, the work is a reminder that paradigm-shifting science doesn’t always require a new molecule — sometimes it requires the courage to swap one out.
Source: University of Florida